仟源医药第一大股东100%持股，被司法冻结

Core Viewpoint - The major shareholder of Qianyuan Pharmaceutical, Zhao Qun, has had 15.78 million shares frozen by the court, representing 100% of his holdings and 6.16% of the company's total shares, due to a pre-litigation preservation request [1][2]. Group 1: Shareholder and Legal Issues - Zhao Qun's shares were frozen due to a court ruling related to a claim made by Cao Xitong, with the frozen amount set at 50 million yuan [1]. - The company clarified that the legal issues involving Zhao Qun are unrelated to the company and do not stem from any overdue debts or violations that could harm the company's interests [2]. Group 2: Company Performance - Qianyuan Pharmaceutical reported a significant decline in net profit for the first half of 2025, with a notable increase in revenue in the third quarter, achieving 238 million yuan, a 14.82% year-on-year growth, and a net profit of approximately 21.95 million yuan, up 106.06% [3]. - Despite the strong quarterly performance, the cumulative results for the first three quarters of 2025 showed a slight revenue increase of 0.44% to 611 million yuan, but a significant drop in net profit by 49.43% to about 22.33 million yuan [3][4]. - Financial expenses have increased by 50.80% year-on-year, reaching approximately 17.52 million yuan, primarily due to rising bank loan interest [4]. Group 3: Market Information - As of February 10, Qianyuan Pharmaceutical's stock closed at 12.00 yuan per share, with a total market capitalization of approximately 3.073 billion yuan [5].